Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Pilot Study Using Hyperthermic Irrigation Followed by Intravesical Chemotherapy in Patients With Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer

The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-mus…

Bladder CancerBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Non-muscle Invasive Bladder Cancer (NMIBC)+6 more

Estimated

~$10 – $6,250

CAMC Health SystemNCT07817173

Phase 3

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

The goal of this study is to learn methods doctors can use to help improve the cystoscopy experience. Specifically, this study will determine if listening to m…

Bladder (Urothelial, Transitional Cell) CancerHematuria

Estimated

~$10 – $7,500

Florian SchroeckNCT07795255

Phase 3

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or …

Bladder (Urothelial, Transitional Cell) CancerNon-Muscle Invasive Bladder CarcinomaNon-muscle Invasive Bladder Cancer With Carcinoma in Situ

Estimated

~$10 – $8,750

Protara TherapeuticsNCT07480356

Observational

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and a…

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) Cancer+16 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07059884

Phase 1

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle in…

Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more

Estimated

~$10 – $8,750

UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.NCT07725796